Guardant Health (GH) PT Lowered to $130 at Stifel
Stifel analyst Daniel Arias lowered the price target on Guardant Health (NASDAQ: GH) to $130.00 (from $160.00) while maintaining a Buy rating.
The analyst commented, "GH finished the year with a good beat and an initial 2022 outlook that includes solid clinical volume growth expectations (50%+ vs. our 36%) but also total revs that come in a bit below the Street ($460-470M vs. Street $473M). In speaking of the environment, management noted a material Covid impact in 1Q, but also improving trends as of late - which made the call sound much like the others in 2021: cautious optimism going forward, but acknowledgement that things are still choppy out there. As we look ahead, we see an improving opportunity for clinical volume-driven beats as holding the potential to grow 1H22 interest in GH shares (at current levels, we would certainly endorse this) - but it's also possible that investors sit and wait on data: the much-awaited ECLIPSE trial results will arrive in 2Q and likely define the stock trajectory for the remainder of the year."